{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:25:40Z","timestamp":1790040340901,"version":"4.0.1"},"reference-count":28,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6,28]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Blinatumomab delays deterioration in HRQL in adults with R\/R ALL.<\/jats:p>","DOI":"10.1182\/blood-2017-09-804658","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T18:20:31Z","timestamp":1525803631000},"page":"2906-2914","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Health-related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab"],"prefix":"10.1182","volume":"131","author":[{"given":"Max S.","family":"Topp","sequence":"first","affiliation":[{"name":"Medizinische Klinik und Poliklinik II, Universit\u00e4tsklinikum W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Cannell","sequence":"additional","affiliation":[{"name":"Fiona Stanley Hospital, Murdoch, Perth, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"Hospital Saint-Louis, University of Paris Diderot, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Leuven, Leuven, Belgium;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[{"name":"City of Hope, Duarte, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Franklin","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qui","family":"Tran","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze","family":"Cong","sequence":"additional","affiliation":[{"name":"Amgen Inc, South San Francisco, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111912155340300_B1","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"12","key":"2019111912155340300_B2","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/cncr.20668","article-title":"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia","volume":"101","author":"Kantarjian","year":"2004","journal-title":"Cancer"},{"issue":"4","key":"2019111912155340300_B3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"12","key":"2019111912155340300_B4","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"issue":"9","key":"2019111912155340300_B5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111912155340300_B6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2019111912155340300_B7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","article-title":"Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials\u2013a systematic review to evaluate the added value in supporting clinical decision making","volume":"44","author":"Efficace","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"2019111912155340300_B8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"issue":"10","key":"2019111912155340300_B9","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/cncr.31317","article-title":"Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"124","author":"Kantarjian","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"2019111912155340300_B10","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","article-title":"Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study","volume":"4","author":"Kantarjian","year":"2017","journal-title":"Lancet Haematol"},{"issue":"5","key":"2019111912155340300_B11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2019111912155340300_B12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11136-013-0583-6","article-title":"Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?","volume":"24","author":"Anota","year":"2015","journal-title":"Qual Life Res"},{"issue":"16","key":"2019111912155340300_B13","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1200\/JCO.2014.56.7974","article-title":"Statistical challenges in the analysis of health-related quality of life in cancer clinical trials","volume":"34","author":"Bonnetain","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111912155340300_B14","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1634\/theoncologist.2011-0085","article-title":"Time to deterioration in quality of life score as a modality of longitudinal analysis in patients with breast cancer","volume":"16","author":"Hamidou","year":"2011","journal-title":"Oncologist"},{"issue":"15","key":"2019111912155340300_B15","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1016\/j.ejca.2010.07.023","article-title":"Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma","volume":"46","author":"Bonnetain","year":"2010","journal-title":"Eur J Cancer"},{"issue":"1","key":"2019111912155340300_B16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111912155340300_B17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/009286150804200402","article-title":"Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials","volume":"42","author":"Mallinckrodt","year":"2008","journal-title":"Drug Inf J"},{"key":"2019111912155340300_B18","doi-asserted-by":"crossref","DOI":"10.1002\/9780470316696","article-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"1987"},{"issue":"6","key":"2019111912155340300_B19","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/BF00439229","article-title":"The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30","volume":"5","author":"King","year":"1996","journal-title":"Qual Life Res"},{"issue":"1","key":"2019111912155340300_B20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111912155340300_B21","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"12","key":"2019111912155340300_B22","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.ejca.2005.05.007","article-title":"Health related quality of life outcomes in cancer clinical trials","volume":"41","author":"Bottomley","year":"2005","journal-title":"Eur J Cancer"},{"key":"2019111912155340300_B23","unstructured":"European Medicines Agency. Report - Oncology Working Party Health Related Quality of Life (HRQoL) workshop 2nd May 2012. EMA\/204419\/2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2012\/12\/WC500135920.pdf. Accessed 6 April 2017."},{"issue":"7","key":"2019111912155340300_B24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1185\/03007995.2016.1164677","article-title":"Burden of hospitalization in relapsed acute lymphoblastic leukemia","volume":"32","author":"Barlev","year":"2016","journal-title":"Curr Med Res Opin"},{"issue":"13","key":"2019111912155340300_B25","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"issue":"30","key":"2019111912155340300_B26","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.2014.55.3453","article-title":"Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes","volume":"32","author":"Efficace","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111912155340300_B27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1026429831234","article-title":"Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer","volume":"6","author":"Osoba","year":"1997","journal-title":"Qual Life Res"},{"issue":"5","key":"2019111912155340300_B28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00451727","article-title":"Psychometric properties and responsiveness of the EORTC quality of Life Questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer","volume":"3","author":"Osoba","year":"1994","journal-title":"Qual Life Res"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/26\/2906\/1466040\/blood804658.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/26\/2906\/1466040\/blood804658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T19:19:49Z","timestamp":1574191189000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/26\/2906\/39156\/Healthrelated-quality-of-life-in-adults-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":28,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2018,6,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-09-804658","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]}}}